IP Library Granted Patent US 9,822,416
Granted Patent B2
US 9,822,416 · App. 13/577,335 · Granted Nov 21, 2017

miRNA in the diagnosis of ovarian cancer

Inventors: Andreas Keller (Puettlingen, DE); Matthias Scheffler (Hirschberg-Leutershausen, DE); Markus Beier (Weinheim, DE)
Assignee: Hummingbird Diagnostics GmbH
C12Q1/6886C12Q2600/156C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,822,416
App. No.
13/577,335
Granted
Nov 21, 2017
Kind
B2
Abstract

The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.

Claims (10)

1. A method of detecting a miRNA expression profile in a human subject, the method comprising:

(a) providing a blood cell sample comprising erythrocytes, leukocytes, and thrombocytes from a human subject;

(b) detecting the expression level of an miRNA set consisting of hsa-miR-342-3p (SEQ ID NO: 442) and hsa-miR-146a (SEQ ID NO: 709) in the blood cell sample using an RT-PCR assay.

2. The method of claim 1 , wherein step (b) comprises:

(i) isolating RNA from the blood cell sample;

(ii) amplifying the isolated RNA to produce an amplified nucleic acid sample;

(iii) contacting the amplified nucleic acid sample with a first probe complementary to hsa-miR-342-3p (SEQ ID NO: 442) and a second probe complementary to hsa-miR-146a (SEQ ID NO: 709); and

(iv) detecting binding of the first and second probes.

3. The method of claim 1 , wherein step (a) comprises obtaining a blood sample from the human subject and isolating a cellular fraction from the blood sample, thereby producing blood cell sample.

4. The method of claim 1 , wherein the human subject is a subject suspected of having ovarian cancer.

Assignments (3)
CHANGE OF NAME Recorded Jun 21, 2017
From: COMPREHENSIVE BIOMARKER CENTER GMBH
To: HUMMINGBIRD DIAGNOSTICS GMBH
Reel/Frame 042928/0606 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2013
From: FEBIT HOLDING GMBH
To: COMPREHENSIVE BIOMARKER CENTER GMBH
Reel/Frame 031784/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2012
From: KELLER, ANDREAS; SCHEFFLER, MATTHIAS; BEIER, MARKUS
To: FEBIT HOLDING GMBH
Reel/Frame 028779/0369 →
Priority Claims (1)
EP 10152809 · Feb 5, 2010 · regional
Continuity (1)
Related Publication 20120309645A1 · Dec 6, 2012